Comparison
Semaglutid vs. Semax
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
910463-68-2
80714-61-0
Molecular weight
4113.6 g/mol
813.92 g/mol
Half-life
165 h
0.3 h
Sequence
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMet-Glu-His-Phe-Pro-Gly-ProMechanism of action
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
4
of which in humans
3
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
5
1